Name | 1-(2,6-Dibromo-4-isopropylphenyl)-3-(3-pyridinyl)urea |
---|---|
Synonyms |
1-(2,6-Dibromo-4-isopropylphenyl)-3-(3-pyridinyl)urea
N-(2,6-dibromo-4-isopropylphenyl)-N'-(3-pyridinyl)urea Urea, N-[2,6-dibromo-4-(1-methylethyl)phenyl]-N'-3-pyridinyl- |
Description | BX430 is a potent and selective noncompetitive allosteric human P2X4 receptor channels antagonist with an IC50 of 0.54 μM. BX430 has species specificity. BX430 is used for chronic pain and cardiovascular disease. |
---|---|
Related Catalog | |
Target |
IC50: 0.54 μM (human P2X4 receptor channels)[1] |
In Vitro | BX430 has virtually no functional impact on all other P2X subtypes, namely, P2X1-P2X3, P2X5, and P2X7, at 10-100 times its IC50[1]. BX430 is a potent antagonist of zebrafish P2X4 but has no effect on rat and mouse P2X4 orthologs[1]. Human P2X4-expressing cells treated with thapsigargin plus BX430 shows a significant reduction in the intracellular calcium rise evoked by ATP[1]. BX430 (5 μM) markedly reduces the amplitude of ATP-evoked intracellular calcium responses in THP-1 cells[1]. |
References |
Density | 1.7±0.1 g/cm3 |
---|---|
Boiling Point | 395.4±42.0 °C at 760 mmHg |
Molecular Formula | C15H15Br2N3O |
Molecular Weight | 413.107 |
Flash Point | 192.9±27.9 °C |
Exact Mass | 410.958160 |
LogP | 4.56 |
Vapour Pressure | 0.0±0.9 mmHg at 25°C |
Index of Refraction | 1.679 |
Hazard Codes | Xn |
---|